Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors [0.03%]
胃肠神经内分泌肿瘤治疗与姑息治疗的新靶点
Scott N Pinchot,Susan C Pitt,Rebecca S Sippel et al.
Scott N Pinchot et al.
Gastrointestinal (GI) neuroendocrine tumors (NETs), for example, carcinoids, are rare neoplasms characterized by the production of bioactive markers, such as 5-HT and chromogranin A. With the exception of surgery, there are limited curative...
Piotr J Wysocki,Jakob Zolnierek,Cezary Szczylik et al.
Piotr J Wysocki et al.
Rapid development of treatment strategies for renal cell cancer (RCC) has occurred in recent years. Elucidation of the crucial role of the Von Hippel-Lindau (VHL) tumor suppressor gene in upregulating growth factors associated with angiogen...
Angela Märten,Markus W Büchler
Angela Märten
Patients with carcinoma of the exocrine pancreas have an especially poor prognosis. This is a systemic disease that is insensitive to radiotherapy and often to chemotherapy. One promising treatment strategy is immunotherapy, and several pha...
David A Gewirtz
David A Gewirtz
Tovaxin, radiation-attenuated, patient-specific T-cells for the therapeutic vaccination of multiple sclerosis [0.03%]
针对多发性硬化症患者的个体化治疗性疫苗——TovaXin放射减毒的患者特异性T细胞疗法
Niels Hellings,Piet Stinissen
Niels Hellings
Opexa Pharmaceuticals Inc is developing Tovaxin, a trivalent formulation of attenuated myelin-peptide-reactive T-cells, for the potential treatment of multiple sclerosis. Tovaxin is being evaluated in phase II clinical trials. Opexa was pre...
XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator [0.03%]
重组分子伴侣蛋白10 XToll的免疫调节作用及其抗炎机制研究
Willem van Eden
Willem van Eden
CBio Ltd, under license from the University of Queensland, is developing a recombinant form of chaperonin 10, known as XToll, for the potential anti-inflammatory treatment of rheumatoid arthritis, psoriasis and multiple sclerosis. All three...
ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases [0.03%]
用于潜在自身免疫疾病治疗的全人源单克隆抗IL-12 / IL-23抗体ABT-874
Changhai Ding,Jianhua Xu,Jun Li
Changhai Ding
ABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor beta1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is cu...
David N Posnett
David N Posnett
Herpesvirus infection, in particular EBV infection, has been implicated in several major autoimmune diseases, including systemic lupus erythematosus (SLE), multiple sclerosis (MS) and rheumatoid arthritis (RA). Herpesvirus infection has pot...
Seeking approval: present and future therapies for pemphigus vulgaris [0.03%]
寻觅皮损控制的良药：寻常型天疱疮的当前及未来疗法
Xuming Mao,Aimee S Payne
Xuming Mao
Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes. Despite the potentially fatal prognosis, there are currently no FDA-approved treatments specifically for pemphigus. In 2006, the FDA designated orphan ...
DNAM-1: an amplifier of immune responses as a therapeutic target in various disorders [0.03%]
DNAM-1：一种免疫反应放大器及其作为各种疾病治疗靶点的潜力
Moran Elishmereni,Ido Bachelet,Francesca Levi-Schaffer
Moran Elishmereni
The co-stimulatory adhesion molecule DNAX accessory molecule 1 (DNAM-1) is a functional glycoprotein expressed on immune cells, such as natural killer and T-cells. It is activated upon interaction with its biological ligands, the poliovirus...